The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro.
AIMS/HYPOTHESIS: Miltefosine, the first oral anti-leishmanial drug, is reported to inhibit phosphatidylinositol 3-kinase (PI3K)/Akt activity in carcinoma cell lines. Inhibition of the PI3K/Akt pathway is known to result in insulin resistance. Therefore, we investigated whether miltefosine has any deleterious effect(s) on insulin sensitivity in L6E9 skeletal muscle cells. MATERIALS AND METHODS: L6E9 myotubes were treated with miltefosine and its effect was observed on insulin-signalling proteins such as Akt, PI3K, insulin receptor-beta, IRS-1, c-Jun N-terminal kinase, p38 and glycogen synthase kinase beta, as well as on glucose uptake. RESULTS: Miltefosine caused skeletal muscle insulin resistance in vitro by interfering with the insulin-signalling pathway and inhibiting insulin-stimulated glucose uptake. CONCLUSIONS/INTERPRETATION: Miltefosine may contribute to the risk of type 2 diabetes and needs further clinical exploration.[1]References
- The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Verma, N.K., Dey, C.S. Diabetologia (2006) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
